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Abstract 
 The main objective of this study is to analyze the prophylactic usage of 
low molecular weight heparin, in women during the period of pregnancy. A 
retrospective study was undertaken during 01 January – 31 December  of 
2013, in the Department of Gynecology and Obstetrics, at Clinical Hospital 
in Tetovo. Data were collected for the following: patient demographics, 
week and month of pregnancy, number of pregnancies for each patient, 
duration of hospital stay, clinical and laboratory investigations, diagnosis, 
drug details; which include the name of the drug, dosage form, dose 
frequency, total cost of the drug, the amount of each given ampoule 
application and the cost for the entire period of hospitalization. 
Among of 643 women whom were prescribed LMWH, 144 of them were 
found hypercoagulable. The majority of patients given LMWH were aged 
25-30 years (56.25 %). For the  biggest number of patients, this was their 
first pregnancy (70.83%). Earliest phase of using LMWH was the second 
month of pregnancy, respectively sixth week. Patients during the ninth 
month, apear to be more affected by hypercoagulable statete. 56 (38.89 %) 
women were in the ninth month of pregnany. Fraxiparine  (nadroparin 
calcium) 3800 IU anti-Factor XA in 0.4 ml was the most prescribed 
anticoagulant, 64 (44.44 %) patients received this therapy. From the total 
number of 144 patients, only 4 of them received LMWH twice a day. 
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Introduction: 
 Anticoagulant treatment for deep-vein thrombosis aims to prevent 
pulmonary embolism and recurrent thrombosis and also to avoid excessive 
bleeding. In addition, both the effect of therapy on the patients' well-being 
and the cost of therapy are factors to be weighed in determining the optimal 
treatment. It is current practice to treat acute venous thrombosis with 
intravenous standard (unfractionated) heparin for at least five days in a dose 
adjusted to lengthen the activated partial-thromboplastin time into a desired 
range (Koopman M, et al, 1989) Pregnancy is classically thought to be a 
hypercoagulable state. Fibrin generation is increased, fibrinolytic activity is 
decreased, levels of coagulation factors II, VII, VIII, and X are all increased, 
free protein S levels are decreased, and acquired resistance to activated 
protein C is common. Uncomplicated pregnancy is accompanied by 
substantial hemostatic activation as indicated by increased markers of 
coagulation activation, such as prothrombin fragment F1+2 and D-dimer( 
Paul E. et al, 2010)  
 The main reason for the increased risk of thromboembolism in 
pregnancy is hypercoagulability, which has likely evolved to protect women 
from the bleeding challenges of miscarriage and childbirth. Women are at a 
4- to 5-fold increased risk of thromboembolism during pregnancy and the 
postpartum period compared with when they are not pregnant. Eighty 
percent of the thromboembolic events in pregnancy are venous, with an 
incidence of 0.49 to 1.72 per 1000 pregnancies. Risk factors include a history 
of thrombosis, inherited and acquired thrombophilia, maternal age greater 
than 35, certain medical conditions, and various complications of pregnancy 
and childbirth (Andra H. James 2009  ). D-dimer assay testing may be used 
as a screening test and/or in combination with venous ultrasound to facilitate 
diagnosis and prediction of a thromboembolic event. D-dimer is a product of 
the degradation of fibrin by plasmin. Therefore, elevated levels indicate 
increased thrombin activity and increased fibrinolysis following fibrin 
formation. The assay employs monoclonal antibodies to detect D-dimer 
fragments. Commercial assays available include at least three accurate and 
reliable products: two rapid enzyme lined immunosorbent assays and a rapid 
whole-blood assay (Rosenberg V et al, 2007  ). On the basis of earlier 
results, low molecular weight heparin (LMWH) ( Forestier, F et al, 1984)( 
Forestier, F et al, 1992), like unfractionated heparin (UFH) ( Flessa, H et al, 
1965 ), does not cross the placenta and is at present considered to be the drug 
of choice for the prophylaxis of VTEs during pregnancy (Greer, I.et al 
1993)(Toglia M. et al 1996)(Pettila V et al, 1999). The use of LMWH has 
several advantages over unfractionated heparin such as longer half-life ( 
Weitz, J.I. 1997), and more stable and predictable pharmacokinetics ( Greer, 
I.A. 1999), which makes possible subcutaneous once or twice daily self-
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administration, with minimal laboratory monitoring. Using the hospital 
records, we achieved to analyze the prophylactic usage of low molecular 
weight heparin during pregnancy. 
 
Matherials and Methods: 
 Surveillance of LMWH usage was done by collecting data for the 
periode January 1 – Decemmber 31, 2013 in the Department of Gynecology 
and Obstetrics, at Clinical Hospital in Tetovo. Data were collected for the 
following: patient demographics, week and month of pregnancy, number of 
pregnancies  for each patient, duration of hospital stay, clinical and 
laboratory investigations, diagnosis, drug details; which include the name of 
the drug, dosage form, dose frequency, total cost of the drug, the amount of 
each given ampoule application and the cost for the entire period of 
hospitalization. The results were computed usig Ms Excel 2008 and the 
results are expressed as percentage ore proportion either as pictorial 
representation in the form of diagrame or tabular form. 
 
Results: 
Socio-Demographic data 
 During the period of one year, 643 women were prescribed LMWH. 
144 of them were diagnosed hypercoagulable. Demographic data of the 
patients are ilustrated in (Table 1). 
Table 1: Patients demographic data 
Parameters Number of patients Percentage 
Age 
< 18 0 0 
18-20 0 0 
21-24 21 14.58 
25-30 81 56.25 
31-35 29 20.14 
>35 13 9.03 
Living place 
Urban 45 31.25 
Rural 99 68.75 
 
Number and current month/week of pregnancy  
For the biggest number of patients, this was their first pregnancy 102 
(70.83%), 23 (15.98% ) patients declared that this is their second pregnancy 
and for  19 patients (13.19%) this was third, fourth ore fifth pregnancy. 
56 (38.89%) women, were in the ninth month of pregnancy, followed 
by 32 (22.22%) in the tenth month. The earliest stage of using LMWH, was 
second month of pregnancy, 2 (1.39%) women received anticoagulant during 
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that month. The detailed explanation about usage of LMWH during months 
of pregnancy, respectively number of patients is given in Figure 1. 
 
Figure 1: Number of patients/month of pergnancy 
 
 Women during ninth month of pregnancy, were most commune 
patients. From analyzed data, we can notice that 34th and 36th week of 
pregnancy, are more affected by hypercoagulable state. 17 (30.36%) patients 
were recorded in each week (Figure 2).  
 
Figure 2: Number of patients in ninth month of pregnancy 
 
Number of prescribed anticoagulants 
 The biggest number of patients, 64 (44.44%) received  Fraxiparine 
(nadroparin calcium) 3800 IU anti-Factor XA in 0.4 ml, followed by them 
with Clexane (enoxaparin) 4000 IU anti- Factor XA in 0.4ml 32 (22.22%). 
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Only one patient received Fraxiparine (nadroparin calcium) 1900 IU anti-
Factor XA in 0.2 ml (Figure 3). 
 140 patients, received a daily dose of anticoagulant, 4 of them, was 
prescribed to take the anticoagulant twice a day. In the Table 2, are ilustrated 
features of those patients. 
Table 2. Features of patiens trated with double dose 
Nr of 
cases 
Patients 
week of 
pregnancy 
Patients diagnosis Received 
therapy 
Number 
of 
ampules 
Case 1 39th Hypercoagulable 
state  
Clexane 4000 26 
Case 2 37th  Hypercoagulable 
state 
Fraxiparine 
0.4 
50 
Case 3 37th Hypercoagulable 
state 
Fraxiparine 
0.4 
28 
Case 4 31th  Hypercoagulable 
state 
Fraxiparine 
0.4 
20 
 
 
Figure 3.  Number of patients / prescribed anticoagulants 
 
Conclusion: 
 After almost three decades of intensive research, LMWH have 
established their niche as an important class of antithrmbotic compounds and 
have  proved to be both: save and effective for the prophylaxis and treatment 
of  venous thromboembolism. Unfractionated heparin is the anticoagulant of   
choice in pregnant women, because unlike warfarin, it does not cross the  
placenta. Low-molecular-weight heparins also do not cross the placenta and 
descriptive studies suggest that they are both safe and effective in pregnancy 
(Weits J.I, 1997). 
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 In the presented study, from 643 pregnant women which received 
LMWH were included only 144 of them, whith the diagnosis 
Hypercoagulable state. 
 The age range 25-30 (56.25%) comprised the highest proportion of 
the patients. Comparatively less cases were foud among the age range over 
35 years (9.03%). The diagnostic patterns showed that women in their ninth 
moth of pregnancy were most afeccted by Hypercoagulable state (38.89%), 
respectively those in 34th and 36th week, represented with 17 patients each 
other. 
 The leading anticoagulant prescribed was Fraxiparine 0.4, prescribed 
in 64 (44.44%) cases.  
 In conclusion, althought current guidelines support use of low dose 
LMWH in women during pregnancy, this might not be sufficient. For as 
much as they are safe for the baby, because they do not allow passing 
placental barrier, this therapy is being used increasingly.  It is 
necessary to improve the habits of prescribing unnecessary usage of low 
molecular weight heparins, thus enhance their irational use. 
 
References: 
 M.M.W. Koopman, et al. “Treatmant of Venous Thrombosis with 
Intravenous Unfractionated Heparin Administered in the Hospital as 
Compared with Subcutaneous Low-Moleculare-Weight-Heparin 
Administered at Home,” New England Journal of Medicine, vol. 334, pp. 
682-687, March 1996  
 Paul E. Marik, M.D., and Lauren A. Plante, Venous Thromboembolic 
Disease and Pregnancy New England Journal of Medicine, vol. 379, pp. 
2025-2033, Jan 2010  
Andra H. James1 Pregnancy-associated thrombosis,Department of Obstetrics 
and Gynecology, Duke University, Durham, NC  
V .A. Rosenberg, C. J. Lockwood, “Thromboembolism in Pregnancy,” 
Obstetrics and Gynecology Clinics, vol. 34, no. 3, pp. 481-500, Sep. 2007 
Forestier, F., Daff os, F. and Capella-Pavlovsky, M. (1984) Low molecular 
weight heparin(PK 10169) does not cross the placenta during the second 
trimester of pregnancy study by direct fetal blood sampling under ultrasound. 
Th romb. Res., 34, 557-560. 
Forestier, F., Sole, Y., Aiach, M., Alhenc Gelas, M. and Daff os, F. (1992) 
Absence of transplacental passage of fragmin (Kabi) during the second and 
the third trimesters of pregnancy. Th romb. Haemost., 67, 180-181. 
Flessa, H.C., Kapstrom, A.B., Glueck, H.I. and Will, J.J. (1965) Placental 
transport of heparin. Am. J. Obstet. Gynecol., 93, 570-573. 
Greer, I.A. and De Swiet, M. (1993) Th rombosis prophylaxis in obstetrics 
and gynaecology. Br. J. Obstet. Gynaecol., 100, 37-40. 
European Scientific Journal July 2015 edition vol.11, No.21  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
118 
M. R. Toglia, J. G. Weg, “Venous thromboembolism durimg pregnancy” 
The New England Journal of Medicine, vol. 335, no. 2, pp. 108-114, July 
1996  
 Pettila, V., Kaaja, R., Leinonen, P., Ekblad, U., Kataja, M. and Ikkala, E. 
(1999) Th romboprophylaxis with low molecular weight heparin (dalteparin) 
in pregnancy. Th romb. Res., 96, 275-282. 
Weitz, J.I. (1997) Low-molecular-weight heparins. N. Engl. J. Med., 337, 
688-698. 
Greer, I.A. (1999) Th rombosis in pregnancy: maternal and fetal issues. 
Lancet, 353,1258-1265. 
J. I. Weitz, “Low-Molecular-Weight-Heparins,” The”  New England Journal 
of Medicine, vol. 337, pp. 688-699, Sep.1997 
 
 
 
 
  
